Our Pipeline

Two lead compounds with:

Laboratory table surface with vials and beakers, several scientists around table
  • Long-acting effects demonstrated by the animal in vivo studies.
  • Multifunctional effect targeting two events in the virus life cycle: reverse transcription and myristoylation of viral proteins.
  • Better anti-HIV profile against multi-drug resistant virus, cell-free, and cell-associated virus when compared with the commercially available drugs.
  • Higher efficacy and reduced toxicity.
  • Sustained delivery.
  • Inhibiting hidden virus in the lymphatic system.

Candidate derivatives have the potential to be used as long-acting anti-HIV agents for HIV treatment and prevention with potential value-added over the current HIV prevention portfolio.

The compounds and their antiviral activities are protected by multiple patents1 2 3.

A number of compounds are under development using a similar strategy against SARS-CoV-2.

Drug
Candidate

Therapeutic
Indication

Discovery

Pre-Clinical

Clinical

VI125

HIV

Long-Acting Anti-HIV

VI128

HIV

Long-Acting Anti-HIV

VI130

SARS-COV2

SARS-COV2

1 Parang, K., Tiwari, R, El-Sayed, N. S. Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals. April 30, 2020, Provisional Patent Application number 63/017,729.

2 Parang, K., Tiwari, R, El-Sayed, N. S. Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals. July 17, 2020, Provisional Patent Application number 63/053349.

3 Parang, K., Doncel, G., Agarwal, H. K. Substituted nucleoside derivatives with antiviral and antimicrobial properties (Divisional Composition and method claims). PCT Patent filed on March 24, 2016 (15/079,918). U.S. Patent Application 2016, 15/079,918, U.S. Patent No. 9,738,678, August 22, 2017.